Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Rubius Therapeutics, Inc. (RUBY) Create: Alert

All | News | Filings
Date FiledTypeDescription
02/22/2023 8-K Quarterly results
02/06/2023 8-K Quarterly results
12/21/2022 8-K Quarterly results
12/14/2022 8-K Quarterly results
12/12/2022 8-K Quarterly results
11/02/2022 8-K Cost Associated with Exit or Disposal Activities, Departure of Directors or Certain Officers; Election of Directors; Appointm...
10/17/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
10/13/2022 8-K Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arran...
09/13/2022 8-K Cost Associated with Exit or Disposal Activities, Other Events, Financial Statements and Exhibits  Interactiv...
Docs: "Rubius Therapeutics Announces Strategic Update Company to Focus on Advancing Next Generation Red Blood Cell-Based Cell Conjugation Platform Initiating Cost-Saving Measures Through Corporate Restructuring; Cash Runway Extended to End of 2023 Discontinuing Ongoing Phase 1 Clinical Trials of RTX-240 and RTX-224 in Advanced Solid Tumors Investor Teleconference and Webcast Scheduled Today at 7:30 a.m. EDT CAMBRIDGE, Mass., September 13, 2022 -- Rubius Therapeutics, Inc. , a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced plans to restructure the Company and align resources to advance its next generation red blood cell-based cell conjugation platform. ..."
08/12/2022 8-K Quarterly results
08/09/2022 8-K Quarterly results
08/01/2022 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing  Interact...
07/14/2022 8-K Quarterly results
07/07/2022 8-K Quarterly results
05/24/2022 8-K Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  ...
Docs: "Rubius Therapeutics Appoints Noubar Afeyan as Chairman of its Board of Directors CAMBRIDGE, Mass., May 24, 2022 – Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is biologically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Noubar Afeyan, Ph.D., co-founder and member of the board of directors of Rubius Therapeutics and chief executive officer of Flagship Pioneering, as chairman of its board of directors. David Epstein who has served as chairman since 2017 will remain a member of the board. “Since we founded Rubius Therapeutics in FlagshipLabs in 2014, my conviction in the transformative potential of the R..."
05/13/2022 8-K Quarterly results
05/10/2022 8-K Quarterly results
Docs: "Rubius Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update Presented Updated Clinical Data from Monotherapy Phase 1 Arm of RTX-240 Clinical Trial in Advanced Solid Tumors, Showing Clinical Responses with Favorable Tolerability in PD-1 Refractory Disease Expanded Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Dosing Patients in Phase 1 Clinical Trial of RTX-224 in Select Solid Tumors; Initial Results Expected 4Q’ 22 or 1Q’ 23 Successfully Scaled Manufacturing to 200L Bioreactors Company Provides Update on Phase 1 Clinical Trial of RTX-321 in Advanced Human Papilloma Virus 16-Positive Cancers CAMBRIDGE, Mass., May 10, 2022 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical compan..."
04/08/2022 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Rubius Therapeutics Reports Updated Clinical Data at AACR from the Ongoing Monotherapy Phase 1 Arm of the Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors Demonstrating Single-Agent Activity and Favorable Tolerability Best Responses Include Partial Responses in Certain Patients with Non-Small Cell Lung Cancer, Metastatic Anal Cancer and Metastatic Uveal Melanoma with No Treatment-Related Grade 3/4 Adverse Events or Dose-Limiting Toxicities as of the Cutoff Date Expanding Ongoing Phase 1 Arm of RTX-240 + Pembrolizumab to Focus on Non-Small Cell Lung Cancer and Renal Cell Carcinoma Management to Host Conference Call Today at 1:15 p.m. EDT to Discuss Clinical Data and Clinical Development Next Steps for RTX-240 CAMBRIDGE, Mass., April 8, 2022 -- Rubius Therapeutics, Inc. , a clini..."
02/25/2022 8-K Quarterly results
11/08/2021 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update U.S. Food and Drug Administration Clears Investigational New Drug Application for RTX-224, Rubius’ Third Oncology Candidate Clinical Results Expected by Year-End or First Quarter 2022 in Phase 1 Trials of Single-Agent RTX-240 in Advanced Solid Tumors and Relapsed/Refractory Acute Myeloid Leukemia Laurence “Larry” Turka, M.D., Promoted to Head of Research & Translational Medicine CAMBRIDGE Mass., November 8, 2021 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today reported third quar..."
08/09/2021 8-K Quarterly results
07/29/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Employment Agreement between Rubius Therapeutics, Inc. and Dannielle Appelhans",
"Rubius Therapeutics Appoints Dannielle Appelhans as Chief Operating Officer CAMBRIDGE Mass., July 29, 2021 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced the appointment of Dannielle Appelhans as chief operating officer, effective August 9, 2021. She will oversee corporate strategy and technical operations. “Dannielle brings significant experience driving corporate strategy for biopharmaceutical organizations as they evolve from early- to late-stage development, with a particular focus on clinical and commercial manufacturing and scaling supply chains,” said P..."
06/28/2021 8-K Quarterly results
05/13/2021 8-K Quarterly results
05/10/2021 8-K Quarterly results
03/18/2021 8-K Quarterly results
03/15/2021 8-K Quarterly results
02/23/2021 8-K Quarterly results
01/11/2021 8-K Quarterly results
11/09/2020 8-K Quarterly results
Docs: "Rubius Therapeutics Reports Third Quarter 2020 Financial Results and Strong Execution Across the Pipeline Completed Dosing of Fourth Cohort in RTX-240 Phase 1/2 Solid Tumor Clinical Trial Dosed First Patient in RTX-240 Phase 1 Relapsed/Refractory Acute Myeloid Leukemia Clinical Trial Filed Investigational New Drug Application with U.S. Food and Drug Administration for RTX-321 for Human Papillomavirus 16-Positive Cancers with Frozen Drug Substance CAMBRIDGE, Mass., November 9, 2020 -- Rubius Therapeutics, Inc. , a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today reported third quarter 2020 financial results and provided an overview of operational progress...."
09/28/2020 8-K Quarterly results
08/10/2020 8-K Quarterly results
06/30/2020 8-K Quarterly results
05/22/2020 8-K Submission of Matters to a Vote of Security Holders
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy